Watch Hill-Rom Holdings'
What analysts say
- Buy, sell, or hold?: Analysts think investors should stand pat on Hill-Rom Holdings with five of nine analysts rating it hold. Analysts like Hill-Rom Holdings better than competitor Invacare overall. One out of three analysts rate Invacare a buy compared to four of nine for Hill-Rom Holdings. Analysts still rate the stock a hold, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $390.5 million in revenue this quarter. That would represent a rise of 8.3% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.54 per share. Estimates range from $0.50 to $0.58.
What our community says
CAPS All-Stars are solidly behind the stock with 96.7% assigning it an outperform rating. The community at large agrees with the All-Stars with 84.9% awarding it a rating of outperform. Fools are keen on Hill-Rom Holdings, though the message boards have been quiet lately with only 34 posts in the past 30 days. The CAPS rating of five out of five stars for Hill-Rom Holdings is far more upbeat than the community assessment.
Hill-Rom Holdings' profit has risen year over year by an average of 64.5%. Revenue has now gone up for three straight quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Hill-Rom Holdings now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.